TROP2 ADC class read-throughs from Q1 2026 readouts

Reading the signal

TROP2 (trophoblast cell-surface antigen 2) is a tumour-associated antigen broadly expressed across solid tumours, with particularly high prevalence in triple-negative breast cancer, hormone-receptor-positive breast cancer, and non-squamous NSCLC. The TROP2-targeted ADC class includes assets with varied payload chemistries (topoisomerase inhibitors, microtubule disruptors), varied drug-antibody ratios, and varied linker stability profiles.

Q1 2026 readouts across the class have done two things:

• Confirmed that the class as a whole produces meaningful response in the relevant populations, with response rates and progression-free survival metrics broadly consistent across the late-stage assets
• Surfaced material differences in toxicity profile, particularly around interstitial lung disease, neuropathy, ocular toxicity and stomatitis, that vary by payload and linker

The patient-selection question is now the live one. TROP2 expression is biologically relevant but the IHC scoring threshold is not standardised across trials. Whether TROP2-low patients benefit at the same level as TROP2-high patients is being addressed by different trial designs in different programs, and the answer is not consistent.

Commercial implications

For sponsors of TROP2-targeted ADCs and adjacent ADC programs:

1. Toxicity differentiation is the commercial differentiation. When the response and PFS metrics are broadly comparable, the toxicity profile decides where in the line the asset is positioned and what combination partners are practical.
2. The biomarker-positioning decision is high-stakes. A TROP2-agnostic label opens a larger eligible population but is harder to defend on response durability data. A TROP2-high label is more defensible but commercially smaller.
3. The community oncology readiness layer matters. ADC toxicity surveillance infrastructure (ILD monitoring, ocular surveillance) is more developed in some markets and centres than in others. The class will be commercially deeper where that infrastructure is in place.

What we are watching

• Patient-selection biomarker validation work and whether the class converges on a TROP2 IHC threshold or moves toward a TROP2-agnostic label
• Sequential-ADC trial designs that test ADC-after-ADC sequences in breast cancer and NSCLC and how those readouts shape line positioning
• Combination readouts with checkpoint inhibitors in NSCLC, where the immune-microenvironment interaction is the biggest open scientific question